Comparing label-free biosensors for pharmacological screening with cell-based functional assays.
The diversity and impact of label-free technologies continues to expand in drug discovery. Two classes of label-free instruments, using either an electrical impedance-based or an optical-based biosensor, are now available for investigating the effects of ligands on cellular targets. Studies of GPCR function have been especially prominent with these instruments due to the importance of this target class in drug discovery. Although both classes of biosensors share similar high sensitivity to changes in cell shape and structure, it is unknown whether these biosensors yield similar results when comparing the same GPCR response. Furthermore, since cell morphology changes induced by GPCRs differ depending on which G-protein is activated, there is potential for these instruments to have differential sensitivities to G-protein signaling. Here 1 impedance (CellKey)- and 2 optical-based instruments (BIND and Epic) are compared using Gi-coupled (ACh M2), Gq-coupled (ACh M1), and Gs-coupled (CRF1) receptors. All 3 instruments were robust in agonist and antagonist modes yielding comparable potencies and assay variance. Both the impedance and optical biosensors showed similar high sensitivity for detecting an endogenous D1/D5 receptor response and a melanocortin-4 receptor inverse agonist (agouti-related protein). The impedance-based biosensor was uniquely able to qualitatively distinguish G-protein coupling and reveal dual signaling by CRF1. Finally, responses with a ligand-gated ion channel, TRPV1, were similarly detectable in each instrument. Thus, despite some differences, both impedance- and optical-based platforms offer robust live-cell, label-free assays well suited to drug discovery and typically yield similar pharmacological profiles for GPCR ligands.
Peters
Matthew F
MF
Lead Generation Department, AstraZeneca Pharmaceuticals LP, Wilmington, Delaware 19810, USA. matt.f.peters@gmail.com
Vaillancourt
François
F
Heroux
Madeleine
M
Valiquette
Manon
M
Scott
Clay W
CW
D000818:Animals; D001681:Biological Assay / Q000379:methods*; D015374:Biosensing Techniques; D016466:CHO Cells; D002477:Cells; D003346:Corticotropin-Releasing Hormone / Q000494:pharmacology; D006224:Cricetinae; D003412:Cricetulus; D003470:Culture Media; D004305:Dose-Response Relationship, Drug; D055808:Drug Discovery; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D006801:Humans; D018721:Muscarinic Agonists / Q000737:chemistry / Q000494:pharmacology; D043643:Receptor, Muscarinic M1 / Q000819:agonists; D043585:Receptor, Muscarinic M2 / Q000819:agonists; D043562:Receptors, G-Protein-Coupled / Q000819:agonists / Q000037:antagonists & inhibitors / Q000378:metabolism; D015203:Reproducibility of Results; D015398:Signal Transduction / Q000187:drug effects; D050916:TRPV Cation Channels / Q000819:agonists
D003470:Culture Media; D018721:Muscarinic Agonists; D043643:Receptor, Muscarinic M1; D043585:Receptor, Muscarinic M2; D043562:Receptors, G-Protein-Coupled; D050916:TRPV Cation Channels; C494482:TRPV1 protein, human; D003346:Corticotropin-Releasing Hormone